


Supplementary Material


Supplementary Figure 1. Change in (A) PHQ-9 scores and (B) GAD-7 scores in the analysis population after treatment with onabotulinumtoxinA; per protocol analysis using last observation carried forward for missing data.



* $P < 0.0001$ compared with baseline.

GAD-7=7-item Generalized Anxiety Disorder scale; PHQ-9=9-item Patient Health Questionnaire.


Supplementary Figure 2. The Percentages of Patients Experiencing a Reduction of ≥ 1 Severity Category for (A) PHQ-9 and (B) GAD-7 in the Analysis Population After Treatment With OnabotulinumtoxinA




GAD-7=7-item Generalized Anxiety Disorder scale; PHQ-9=9-item Patient Health Questionnaire.

Supplementary Figure 3. Change in PHQ-9 scores from baseline based on observed data for patients with (A) mild, (B) moderate, (C) moderately severe, and (D) severe symptoms of depression at baseline.


A




B



C



D




PHQ-9=9-item Patient Health Questionnaire.


*Indicates $P < 0.0001$ versus baseline.

Supplementary Figure 4. Change in GAD-7 scores from baseline based on observed data for patients with (A) mild, (B) moderate, and (C) severe symptoms of anxiety at baseline.


A



B



C



GAD-7=7-item Generalized Anxiety Disorder scale.

*Indicates $P < 0.0001$ versus baseline.